Martin L. Katz, PhD
- Email: email@example.com
University of Missouri – Columbia (MU)
My laboratory in engaged in developing therapies for inherited neurodegenerative and retinal degenerative disorders. Using canine models, we conduct preclinical therapeutic studies that serve as the basis for initiation of human clinical trials. Our current focus is on direct and ex-vivo gene therapy approaches. One of our treatments is in late stage clinical trials and the another is being prepared for submission to the Food and Drug Administration for approval to conduct an investigational new drug clinical trial.